Sanofi And Genzyme Still At War
Sanofi-aventis has told Genzyme to stand aside and let the shareholders decide on whether an acquisition should take place.
Sanofi-aventis has told Genzyme to stand aside and let the shareholders decide on whether an acquisition should take place. In the latest update in the ongoing sanofi-aventis/Genzyme acquisition battle, the CEOs of both companies have exchanged harsh letters.
Genzyme has a number of defences in place, including a shareholder rights plan or “poison pill”, which may prevent a hostile takeover. According to sanofi-aventis CEO, Christopher Viehbacher, however, this is unfair for shareholders.
“We believe it would be inappropriate for the Board to take these defensive actions,” said Viehbacher in a letter. “If we are unable to have a direct dialogue with you, in all fairness you should allow your shareholders the opportunity to decide for themselves whether or not to accept our proposal.”
Additionally, Genzyme is wielding the threat of the Massachusetts anti-takeover status, which would prevent the acquisition from taking place without Board approval, regardless of shareholders’ opinion, and has also indicated that the Board can extend the election terms of two-thirds of its current directors to an additional 1–3 years.
“Your shareholders should know with certainty that you will not interfere with their right to benefit from our offer,” said Viehbacher. “Therefore, we ask that you take action to make the Massachusetts anti-takeover status inapplicable to our offer and confirm that Genzyme’s 2011 annual meeting of shareholders, including the election of all directors, will be held on schedule.”
Viehbacher also requested a meeting with Genzyme to discuss the proposed acquisition, but in a firm response, Genzyme CEO Henri Termeer, explained that the current $69 per share offer is not an appropriate starting point for discussions. He highlighted the reports Genzyme has released about its near-term plans and future prospects, as well as the results of an independent third party study of the significant revenue potential of its multiple sclerosis candidate alemtuzumab.
“Sanofi-aventis, for its own purposes, has chosen to dismiss or ignore this information and stick to its opportunistic and inadeuqate $69.00 per share offer, even as analysts have adjusted their target to reflect the new information,” said Termeer. He also added that Genzyme continues to have the support of its shareholders.
He makes no mention of taking the actions Viehbacher requested, although he did explain that the Board is open to discussions with sanofi if an appropriate offer is made.
The current tender offer for all the outstanding shares of Genzyme will expire on 10 December.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
